Search

Displaying results 1381 - 1390 of 2518 in total
  1. Drug

    Cannabinol

    go.drugbank.com/drugs/DB14737
    Investigational

    Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inhibitors
  2. Drug

    Narlaprevir

    go.drugbank.com/drugs/DB14760
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    AZD-1656

    go.drugbank.com/drugs/DB14810
    Investigational

    AZD-1656 is under investigation in clinical trial NCT00747175 (A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes).

  4. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is ...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  5. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  6. Drug

    Lonapegsomatropin

    go.drugbank.com/drugs/DB16220
    ApprovedInvestigational

    Lonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone (somatropin) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to ...

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inducers
  7. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to t...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  8. Drug

    Miricorilant

    go.drugbank.com/drugs/DB16234
    Investigational

    Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  9. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with ...

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors
  10. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is under investigation in several clinical trials for its safety and ef...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates